Contineum (CTNM) announced authorization of its investigational new drug, or IND, application from FDA for PIPE-791 for the treatment of chronic pain associated with two separate indications, ...
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback